• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    George Robert E. bought $10,000 worth of shares (14,493 units at $0.69), increasing direct ownership by 8,678% to 14,660 units (SEC Form 4)

    12/27/23 7:31:57 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MBRX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    George Robert E.

    (Last) (First) (Middle)
    C/O MOLECULIN BIOTECH, INC.
    5300 MEMORIAL DR., SUITE 950

    (Street)
    HOUSTON TX 77007

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Moleculin Biotech, Inc. [ MBRX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/26/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/26/2023 P 14,493 A $0.69 14,660 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Jonathan P. Foster by Power of Attorney 12/27/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MBRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MBRX

    DatePrice TargetRatingAnalyst
    6/9/2025$4.00Buy
    H.C. Wainwright
    2/12/2025Buy → Hold
    Maxim Group
    7/18/2022$14.00Outperform
    Oppenheimer
    More analyst ratings

    $MBRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Moleculin Announces $5.9 Million Public Offering

      HOUSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the pricing of a public offering consisting of 16,080,000 shares of common stock (or pre-funded warrants in lieu thereof) and Series E warrants to purchase up to 48,240,000 shares of its common stock, at a combined public offering price per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying Series E warrants of $0.37. The Series E warrants will have an exercise price of $0.37 per share, are exercisable upon sto

      6/20/25 9:20:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

      Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer  FDA recommends inclusion of patients as young as 6 months – younger than Moleculin had proposed – to be allowed in the pediatric clinical study Enrollment and dosing are ongoing in pivotal, adaptive design Phase 3 MIRACLE trial of Annamycin in adult patients with R/R AML; Initial data readout is on track for the second half of 2025 HOUSTON, June 18, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral

      6/18/25 7:30:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Participates in Virtual Investor "What This Means" Segment

      Globally recognized Oncology Key Opinion Leader, Brian Andrew Van Tine, MD, PhD, discusses the positive topline results from the U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) Watch the "What This Means" segment here HOUSTON, June 11, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it participated in a Virtual Investor "What This Means" segment. For the segment, Brian Andrew Van Tine, MD, PhD, Professor of Medicine, Washington Un

      6/11/25 9:15:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Foster Jonathan P. bought $20,000 worth of shares (28,986 units at $0.69), increasing direct ownership by 56% to 80,556 units (SEC Form 4)

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      12/27/23 7:32:37 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • George Robert E. bought $10,000 worth of shares (14,493 units at $0.69), increasing direct ownership by 8,678% to 14,660 units (SEC Form 4)

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      12/27/23 7:31:57 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Klemp Walter V bought $129,999 worth of shares (188,404 units at $0.69), increasing direct ownership by 38% to 680,880 units (SEC Form 4)

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      12/27/23 7:31:05 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBRX
    SEC Filings

    See more
    • Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Moleculin Biotech, Inc. (0001659617) (Filer)

      6/18/25 7:30:21 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-1/A filed by Moleculin Biotech Inc.

      S-1/A - Moleculin Biotech, Inc. (0001659617) (Filer)

      6/16/25 4:19:36 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-1/A filed by Moleculin Biotech Inc.

      S-1/A - Moleculin Biotech, Inc. (0001659617) (Filer)

      6/11/25 5:30:12 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care